Search

Displaying results 6501 - 6510 of 10000 in total
  1. Drug

    EGT-301

    go.drugbank.com/drugs/DB17649
    Experimental

    It consists of an adeno-associated viral vector serotype 9 (AAV9) containing the human Iduronate-2-sulfatase (I2S) transgene designed to restore I2S functional deficiency in patients with Hunter syndrome

  2. Drug

    Zonampanel anhydrous

    go.drugbank.com/drugs/DB20448
    Investigational

    Zonampanel anhydrous is under investigation in clinical trial NCT00044070 (A Study to Evaluate the Effects of YM872 on Stroke Lesion Volume in Acute Stroke Patients).

  3. Drug

    Risovalisib

    go.drugbank.com/drugs/DB21474
    Investigational

    Risovalisib is under investigation in clinical trial NCT05043922 (A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma).

  4. Drug

    Rifalazil

    go.drugbank.com/drugs/DB04934
    Investigational

    Rifalazil is a derivative of the antibiotic rifamycin. It is being investigated by ActivBiotics for the treatment of various bacterial infections.

  5. Drug

    Verubecestat

    go.drugbank.com/drugs/DB12285
    Investigational

    In the study, administration of Verubecestat at doses of 12, 40 and 60 mg resulted in a dose-dependent and sustained reduction in the levels of Ab40, a measure of BACE1 activity, in CSF from baseline of … Verubecestat is under investigation for the treatment of Alzheimer's Disease, Prodromal Alzheimer's disease, and Amnestic Mild Cognitive Impairment.

  6. Drug

    Vicasinabin

    go.drugbank.com/drugs/DB21587
    Investigational

    Vicasinabin is under investigation in clinical trial NCT04265261 (A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic

  7. Drug

    MLN2222

    go.drugbank.com/drugs/DB06503
    Experimental

    MLN2222 is a novel, proprietary recombinant protein that blocks both the C3 and C5 convertases, which are essential components of the complement activation pathway.

  8. Drug

    Lintitript

    go.drugbank.com/drugs/DB04867
    Experimental

    Lintitript is a new, highly specific and potent CCK-A receptor antagonist.

  9. Drug

    R343

    go.drugbank.com/drugs/DB06316
    Investigational

    R343, was investigated in clinical trial NCT01591044 to evaluate its safety and efficacy in patients with mild to moderate asthma.

  10. Drug

    SGS518

    go.drugbank.com/drugs/DB05042
    Experimental

    SGS518, a novel antagonist for the 5HT6 subtype of the serotonin receptor, is being developed as a treatment for Cognitive Impairment Associated with Schizophrenia (CIAS).